|
1
|
Kelly RJ, Petrini I, Rajan A, Wang Y and
Giaccone G: Thymic malignancies: From clinical management to
targeted therapies. J Clin Oncol. 29:4820–4827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Engels EA and Pfeiffer RM: Malignant
thymoma in the United States: Demographic patterns in incidence and
associations with subsequent malignancies. Int J Cancer.
105:546–551. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lemma GL, Lee JW, Aisner SC, Langer CJ,
Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of
carboplatin and paclitaxel in advanced thymoma and thymic
carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo K and Monden Y: Therapy for thymic
epithelial tumors: A clinical study of 1,320 patients from Japan.
Ann Thorac Surg. 76:878–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirai F, Yamanaka T, Taguchi K, Daga H,
Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, et al: A
multicenter phase II study of carboplatin and paclitaxel for
advanced thymic carcinoma: WJOG4207L. Ann Oncol. 26:363–368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giaccone G, Ardizzoni A, Kirkpatrick A,
Clerico M, Sahmoud T and van Zandwijk N: Cisplatin and etoposide
combination chemotherapy for locally advanced or metastatic
thymoma. A phase II study of the European organization for research
and treatment of cancer lung cancer cooperative group. J Clin
Oncol. 14:814–820. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fornasiero A, Daniele O, Ghiotto C, Piazza
M, Fiore-Donati L, Calabró F, Rea F and Fiorentino MV: Chemotherapy
for invasive thymoma. A 13-year experience. Cancer. 68:30–33. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Agatsuma T, Koizumi T, Kanda S, Ito M,
Urushihata K, Yamamoto H, Hanaoka M and Kubo K: Combination
chemotherapy with doxorubicin, vincristine, cyclophosphamide, and
platinum compounds for advanced thymic carcinoma. J Thorac Oncol.
6:2130–2134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levallet G, Bergot E, Antoine M, Creveuil
C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet
J, Morin F, et al: High TUBB3 expression, an independent prognostic
marker in patients with early non-small cell lung cancer treated by
preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang CL, Kadota K, Liu D, Ueno M,
Nakasima N, Ishikawa S, Gotoh M, Misaki N, Chang SS and Yokomise H:
Expression of ERCC1 and class III β-tubulin is associated with the
survival of resected stage III non-small cell lung cancer patients
treated with induction chemoradiotherapy using carboplatin-taxane.
Exp Ther Med. 1:445–451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sève P and Dumontet C: Is class III
beta-tubulin a predictive factor in patients receiving
tubulin-binding agents? Lancet Oncol. 9:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaira K, Takahashi T, Murakami H, Shukuya
T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, et al:
The role of βIII-tubulin in non-small cell lung cancer patients
treated by taxane-based chemotherapy. Int J Clin Oncol. 18:371–379.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferrandina G, Zannoni GF, Martinelli E,
Paglia A, Gallotta V, Mozzetti S, Scambia G and Ferlini C: Class
III beta-tubulin overexpression is a marker of poor clinical
outcome in advanced ovarian cancer patients. Clin Cancer Res.
12:2774–2779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vilmar AC, Santoni-Rugiu E and Sørensen
JB: Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype
predicts superior outcome in a randomized trial. Clin Cancer Res.
17:5205–5214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edelman MJ, Schneider CP, Tsai CM, Kim HT,
Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L
and Reck M: Randomized phase II study of ixabepilone or paclitaxel
plus carboplatin in patients with non-small-cell lung cancer
prospectively stratified by beta-3 tubulin status. J Clin Oncol.
31:1990–1996. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roque DM, Buza N, Glasgow M, Bellone S,
Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M,
et al: Class III β-tubulin overexpression within the tumor
microenvironment is a prognostic biomarker for poor overall
survival in ovarian cancer patients treated with neoadjuvant
carboplatin/paclitaxel. Clin Exp Metastasis. 31:101–110. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roque DM, Bellone S, English DP, Buza N,
Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M,
et al: Tubulin-β-III overexpression by uterine serous carcinomas is
a marker for poor overall survival after platinum/taxane
chemotherapy and sensitivity to epothilones. Cancer. 119:2582–2592.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasegawa S, Miyoshi Y, Egawa C, Ishitobi
M, Taguchi T, Tamaki Y, Monden M and Noguchi S: Prediction of
response to docetaxel by quantitative analysis of class I and III
beta-tubulin isotype mRNA expression in human breast cancers. Clin
Cancer Res. 9:2992–2997. 2003.PubMed/NCBI
|
|
20
|
Paradiso A, Mangia A, Chiriatti A, Tommasi
S, Zito A, Latorre A, Schittulli F and Lorusso V: Biomarkers
predictive for clinical efficacy of taxol-based chemotherapy in
advanced breast cancer. Ann Oncol. 16 Suppl 4:iv14–iv19. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hwang JE, Hong JY, Kim K, Kim SH, Choi WY,
Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, et al: Class III
β-tubulin is a predictive marker for taxane-based chemotherapy in
recurrent and metastatic gastric cancer. BMC Cancer. 13:4312013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu J, Gao J, Lu Z, Gong J, Li Y, Dong B,
Li Z, Zhang X and Shen L: Combination of microtubule associated
protein-tau and β-tubulin III predicts chemosensitivity of
paclitaxel in patients with advanced gastric cancer. Eur J Cancer.
50:2328–2335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nitiss JL: DNA topoisomerase II and its
growing repertoire of biological functions. Nat Rev Cancer.
9:327–337. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dingemans AM, Witlox MA, Stallaert RA, van
der Valk P, Postmus PE and Giaccone G: Expression of DNA
topoisomerase IIalpha and topoisomerase IIbeta genes predicts
survival and response to chemotherapy in patients with small cell
lung cancer. Clin Cancer Res. 5:2048–2058. 1999.PubMed/NCBI
|
|
25
|
Ceppi P, Longo M, Volante M, Novello S,
Cappia S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M
and Scagliotti GV: Excision repair cross complementing-1 and
topoisomerase IIalpha gene expression in small-cell lung cancer
patients treated with platinum and etoposide: A retrospective
study. J Thorac Oncol. 3:583–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dingemans AC, van Ark-Otte J, Span S,
Scagliotti GV, van der Valk P, Postmus PE and Giaccone G:
Topoisomerase IIalpha and other drug resistance markers in advanced
non-small cell lung cancer. Lung Cancer. 32:117–128. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Knoop AS, Knudsen H, Balslev E, Rasmussen
BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE,
Mouridsen H, et al: Retrospective analysis of topoisomerase IIa
amplifications and deletions as predictive markers in primary
breast cancer patients randomly assigned to cyclophosphamide,
methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and
fluorouracil: Danish breast cancer cooperative group. J Clin Oncol.
23:7483–7490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH,
Chu M, Li W, Zhuang G and Gao WQ: TOP2Ahigh is the phenotype of
recurrence and metastasis whereas TOP2Aneg cells represent cancer
stem cells in prostate cancer. Oncotarget. 5:9498–9513. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Masaoka A: Staging system of thymoma. J
Thorac Oncol. 5 10 Suppl 4:S304–S312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Travis W, Brambilla W, Müller-Hermelink H
and Harris C: Chapter 3. Tumors of the thymus. World health
organization classification of tumorsPathology and genetics of
tumors of the lung, pleura, thymus and heart. IARC press; 3rd.
Lyon: 2004
|
|
31
|
Shimizu K, Kaira K, Tomizawa Y, Sunaga N,
Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M,
et al: ASC amino-acid transporter 2 (ASCT2) as a novel prognostic
marker in non-small cell lung cancer. Br J Cancer. 110:2030–2039.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Buck AC, Schirrmeister HH, Guhlmann CA,
Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T
and Reske SN: Ki-67 immunostaining in pancreatic cancer and chronic
active pancreatitis: Does in vivo FDG uptake correlate with
proliferative activity? J Nucl Med. 42:721–725. 2001.PubMed/NCBI
|
|
33
|
Kaira K, Serizawa M, Koh Y, Miura S, Kaira
R, Abe M, Nakagawa K, Ohde Y, Okumura T, Naito T, et al: Expression
of excision repair cross-complementation group 1, breast cancer
susceptibility 1, and β III-tubulin in thymic epithelial tumors. J
Thorac Oncol. 6:606–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McCarroll JA, Gan PP, Liu M and Kavallaris
M: betaIII-tubulin is a multifunctional protein involved in drug
sensitivity and tumorigenesis in non-small cell lung cancer. Cancer
Res. 70:4995–5003. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McCarroll JA, Gan PP, Erlich RB, Liu M,
Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH,
et al: TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis
to promote tumorigenesis and anoikis resistance in non-small cell
lung cancer. Cancer Res. 75:415–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCarroll JA, Sharbeen G, Liu J, Youkhana
J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan
M, et al: βIII-tubulin: A novel mediator of chemoresistance and
metastases in pancreatic cancer. Oncotarget. 6:2235–2249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
National Comprehensive Cancer Network
(NCCN), . NCCN clinical practice guidelines in oncology. Thymomas
and thymic carcinomas version 1. 2015.https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf
|
|
38
|
Galmarini CM, Treilleux I, Cardoso F,
Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M,
Larsimont D, Piccart MJ, et al: Class III beta-tubulin isotype
predicts response in advanced breast cancer patients randomly
treated either with single-agent doxorubicin or docetaxel. Clin
Cancer Res. 14:4511–4516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burgess DJ, Doles J, Zender L, Xue W, Ma
B, McCombie WR, Hannon GJ, Lowe SW and Hemann MT: Topoisomerase
levels determine chemotherapy response in vitro and in vivo. Proc
Natl Acad Sci USA. 105:pp. 9053–9058. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Desmedt C, Di Leo A, de Azambuja E,
Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C,
Kains JP, Carly B, et al: Multifactorial approach to predicting
resistance to anthracyclines. J Clin Oncol. 29:1578–1586. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tinari N, Lattanzio R, Natoli C,
Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P,
Alberti S, Piantelli M and Iacobelli S: Changes of topoisomerase
IIalpha expression in breast tumors after neoadjuvant chemotherapy
predicts relapse-free survival. Clin Cancer Res. 12:1501–1506.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ferrandina G, Petrillo M, Carbone A,
Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A
and Scambia G: Prognostic role of topoisomerase-IIalpha in advanced
ovarian cancer patients. Br J Cancer. 98:1910–1915. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu JM, Wang LS, Huang MH, Hsu WH, Yen SH,
Shiau CY, Li AF, Tiu CM, Tseng SW and Huang BS: Topoisomerase
2alpha plays a pivotal role in the tumor biology of stage IV thymic
neoplasia. Cancer. 109:502–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY,
Yu CJ, Lin CC, Huang TC, Yang PC and Yang CH: Gemcitabine plus
conventional-dose epirubicin versus gemcitabine plus cisplatin as
first-line chemotherapy for stage IIIB/IV non-small cell lung
carcinoma-a randomized phase II trial. Lung Cancer. 62:334–343.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY,
Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression
in hepatocellular carcinoma correlates with early age onset,
shorter patients survival and chemoresistance. Int J Cancer.
124:644–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pichierri P, Franchitto A, Mosesso P, de
Santis L Proietti, Balajee AS and Palitti F: Werner's syndrome
lymphoblastoid cells are hypersensitive to topoisomerase II
inhibitors in the G2 phase of the cell cycle. Mutat Res.
459:123–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Terry SY, Riches AC and Bryant PE:
Suppression of topoisomerase IIalpha expression and function in
human cells decreases chromosomal radiosensitivity. Mutat Res.
663:40–45. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bryant PE, Riches AC, Shovman O, Dewar JA
and Adamson DJ: Topoisomerase IIα levels and G2 radiosensitivity in
T-lymphocytes of women presenting with breast cancer. Mutagenesis.
27:737–741. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim JS, Kim SY, Lee M, Kim SH, Kim SM and
Kim EJ: Radioresistance in a human laryngeal squamous cell
carcinoma cell line is associated with DNA methylation changes and
topoisomerase IIα. Cancer Biol Ther. 16:558–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
